Restart Life Sciences Corp.
HEAL
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 102.63% | 130.58% | 87.15% | 37.44% | -45.98% |
| Depreciation & Amortization | -25.00% | -23.53% | -22.22% | -21.05% | -20.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 102.75% | 130.24% | 87.06% | 31.29% | -49.08% |
| Operating Income | -102.75% | -118.67% | -87.22% | -31.38% | 49.06% |
| Income Before Tax | -700.86% | -9,169.79% | 18.06% | 51.95% | 118.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -700.86% | -9,169.79% | 18.06% | 51.95% | 118.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -700.86% | -9,169.79% | 18.06% | 51.95% | 118.05% |
| EBIT | -102.75% | -118.67% | -87.22% | -31.38% | 49.06% |
| EBITDA | -103.20% | -119.31% | -87.64% | -31.55% | 49.12% |
| EPS Basic | -399.09% | -6,100.00% | 90.48% | 92.67% | 117.77% |
| Normalized Basic EPS | 2.65% | -31.03% | -23.98% | 5.30% | 51.16% |
| EPS Diluted | -630.14% | -383.78% | 85.33% | 87.38% | 110.18% |
| Normalized Diluted EPS | -2.79% | -27.91% | -18.88% | 9.09% | 53.75% |
| Average Basic Shares Outstanding | 121.69% | 90.80% | 55.51% | 23.90% | 4.11% |
| Average Diluted Shares Outstanding | 113.59% | 92.29% | 59.43% | 27.83% | 8.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |